International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 5, Issue 2, pp: (548-554), Month: October 2017 - March 2018, Available at: www.researchpublish.com

Use of Two Agents Calcium Channels Blockers (CCBs) In Angina

[1]Mamdouh Eidhah Alharthi, [2]Ahmad Othman Almailabi, [3]Ahmed Taher Altayeb

Abstract: **In this article, we explain the clinical roles of CCBs in angina, dual calcium channel therapy and contraindications. We performed an electronic search through Medline, and Embase databases (up to November 2017) for publications, we limited our search to English language Articles, and to every study discussing Calcium Channels blockers (CCBs) effectiveness in angina. CCBs inhibit Ca2+ channels in the myocardium or vascular smooth muscular tissue cells, resulting in inhibition of myocardium contraction, inhibition of ICS (anti-arrhythmias) and vasodilation. Moreover, CCBs have a pleiotropic effect on CSA including alternative angina, MI and ST. Furthermore, new systems of action of Ca2+ channels, such as the aldosterone inhibition effect and mineralocorticoid receptor blockade impact, have been illuminated in the field of endocrinology. All the calcium blockers have been utilized for managing angina. Nevertheless, the most commonly utilized calcium blockers are the longer-acting types of diltiazem and verapamil, amlodipine, or felodipine.**

Keywords: **Calcium Channels blockers (CCBs), effectiveness in angina.**

1. INTRODUCTION

Calcium (Ca) channel blockers (CCBs) wased initially reported in 1969, when Fleckenstein et al. [1] in Germany described prenylamine, verapamil and D600 (methoxyverapamil) as coronary vasodilators. Fleckenstein identified these agents Ca antagonists, not CCBs, on the basis of their pharmacological impacts including vascular and myocardial stretch activation. These medicines also exert powerful actions on coronary vessels and various other smooth muscles, relaxing vascular smooth muscle, uterine smooth muscle and intestinal smooth muscle. The idea of the CCB occurred from the advent of the 1,4-dihydropyridine derivative nifedipine (Adalat), which was developed by Vater et al. [2] in Germany in 1972, and from basic and clinical studies performed by Fleckenstein et al. [3] in Germany and by Hashimoto et al. [4] in Japan. Nifedipine is efficient for the therapy of ischemic heart illness due to the fact that it enhances coronary blood flow [5] and has a hypotensive impact [6].Diltiazem (Herbesser) was developed in Japan [7] and its effectiveness in alternative angina has been demonstrated [8].Many pharmaceutical companies have shown interest in CCBs; therefore, numerous CCBs have been developed. CCBs are medications that target voltage-dependent Ca channels, and new categories based on subtypes of Ca channels and α1 subunits have been proposed [9].

In this article, we explain the clinical roles of CCBs in angina, dual calcium channel therapy and contraindications.

2. METHODOLOGY

We performed an electronic search through Medline, and Embase databases (up to November 2017) for publications, we limited our search to English language Articles, and to every study discussing Calcium Channels blockers (CCBs) effectiveness in angina. Publications of any type were included if they reported original data from such safety and efficiency of CCBs. Bibliographies of all identified reviews and original research publications were hand searched for additional studies.

3. DISCUSSION

- **GENERAL BACKGROUND:**

CCBs bind to voltage-dependent Ca channels in the cell membrane and prevent the influx of Ca ions right into cells. The voltage-dependent Ca channel family members reveal differences in the potential threshold of depolarization and are

classified as high-voltage-activated or low-voltage-activated forms based on their membrane possible dependence. The high-voltage-activated forms consist of the slow L (long-lasting) kind with inert speed, N (neural) types, which exist in regions such as the nerve terminals and P/Q types, which are identified as subtypes of the R type. The low-voltage-activated kind includes only the T (transient) kind, which has a fast transient inactivation rate, is mainly L-shaped in the myocardium and vascular smooth muscular tissue, and is associated with the T-type pacemaker activity of the sinoatrial node and nerve cells. The Ca channel includes five subunits (α1, α2, β, γ and δ), each encoded by a different gene9 The α1 subunit is one of the most essential; it develops the Ca2+ permeation pore and contains a membrane potential detection sensor and the phosphorylation site, which is customized during intracellular signal transduction. CCBs are categorized right into the dihydropyridine (DHP) type, the phenylalkylamine (PAA) kind or the benzodiazepine (BTZ) type. They have likewise been classified into three generations based on the timing of their exploration and duration of their action. The first-generation CCBs have a short duration of action and lead to a tachycardia reflex, which is problematic. In the second generation, a sustained-release formulation was created with long-lasting, steady activity and long-acting antihypertensive impacts. The third-generation CCBs, such as amlodipine (Amlodine) and azelnidipine (Calblock), have a lengthy period of activity, produce a tiny tachycardia reflex, and have high vascular selectivity. The DHP-type CCBs have a high affinity for Ca channels in vascular smooth muscular tissue cells with low membrane potential and have higher activity in vessels compared to in cardiac muscular tissue cells. They act strongly on vascular smooth muscle, exerting a strong hypotensive effect through outer vasodilatation. By contrast, the PAA kind CCBs, such as verapamil (Vasolan), act on the impulse conduction system (ICS) with high membrane potential and on Ca channels in ventricular muscle mass, and have adverse inotropic, chronotropic and dromotropic effects. The BTZ kind, diltiazem, exerts an intermediate result between the DHP kind and PAA kind, acting upon the myocardium and ICS, particularly in atrioventricular node transmission. Most recently, the diarylaminopropylamine drug bepridil (Bepricor) has been established (Table 1) [10].

CCBs have pleiotropic impacts, such as anti-inflammatory effects, antioxidant effects, inhibition of the movement and proliferation of vascular smooth muscular tissue cells, improved nitric oxide (NO) production, [11] plaque stablizing, inhibition of blood vessel aggregation, vasodilation, decreased cardiac contraction and heart rate, and reduced atrioventricular conduction. Nifedipine is known to increase the levels of adiponectin [12] and peroxisome proliferatoractivated receptor-γ, [13] which raise the expression of transcription elements involved in adipocyte differentiation. Moreover, nifedipine has an antioxidant impact, [14] boosts NO bioavailability [12], [14] and inhibits vascular smooth muscle migration [15].Additionally, it prevents monocyte chemotactic protein-1 expression, [16] therefore causing anti-inflammatory activity, and is also understood to improve vascular improvement. Amlodipine has a feasible inhibitory effect on the start and progression of atherosclerosis via NO manufacturing, [17] has anti-inflammatory [18] and antioxidant effects, [19] prevents the migration and proliferation of vascular smooth muscle cells, maintains plaques [20] and prevents platelet aggregation, as revealed by basic science and clinical experiments.The adverse effects of CCBs include palpitations, headache, warm flashes, edema, gingival growth and irregularity. Non-DHP CCBs need to not be used in patients with heart failure or marked bradycardia due to their cardioinhibitory actions, and careful consideration is essential regarding their use in elderly patients with latent cardiac disorders or their concomitant use with digitalis or a β-blocker [21].

Table 1.Classification of calcium channel blockers

Classifications	Drugs	Representative drugs	Action time	Ca2+ channel	Metabolism	Main effect
Dihydropyridine derivative:						Negative inotropic effect
1st generation	Nifedipine	Adalat	Short	L	CYP3A4	CSA↓
	Nicardipine	Perdipine	Short	L	CYP3A4	Vasodilation
2nd generation(a)	Nifedipine	Adalat L	Long	L	CYP3A4	
	Nicardipine	Perdipine LA	Long	L	CYP3A4	
2nd generation(b)	Nilvadipine	Nivadil	Mid	L	CYP3A4	
	Nisoldipine	Baymycard	Mid	L	CYP3A4	
	Nitrendipine		Mid	L	CYP3A4	
	Manidipine	Calslot	Mid	L	CYP3A4	
	Benidipine	Conil	Short	L	CYP3A4	
	Barnidipine		Mid	L	CYP3A4	
	Efonidipine	Landel	Short	L,T	CYP3A4	
	Felodipine		Short	L	CYP3A4	
	Cilnidipine	Atelec	Short	L,N	CYP3A4	

3rd generation	Aranidipine Amlodipine azelnidipine	Norvasc Calblock	Short Long Long	L L,N L	CYP3A4 CYP3A4 CYP3A4	
Benzodiazepine derivative **1st generation** **2nd generation(a)**	Diltiazem Diltiazem	Herbesser Herbesser R	Mid Mid	L L	CYP3A4	Negative inotropic effect CYP3A4 ,CSA↓ Vasodilation Negative inotropic effect
Phenylalkylamine derivative **1st generation**	Verapamil	Vasolan	Short	L	CYP3A4	ICS↓
Diarylaminoproplamine derivative **3rd generation**	Bepridil	Bepricor	Long	L,N	CYP2D6	Negative inotropic effect ICS↓

- **Contraindications, Adverse Effects, and Drug Interactions of CCBs:**

All CCBs are contraindicated in patients who are hypersensitive to any type of component of a provided preparation. Verapamil and diltiazem are contraindicated in patients with hypotension, sick sinus syndrome (unless a permanent pacemaker is in place), second- or third-degree atrioventricular block, and patients with atrial flutter or atrial fibrillation and an accessory bypass tract (eg, Wolff-Parkinson-White or Lown-Ganong-Levine disorders). In addition, verapamil is contraindicated in patients with severe left ventricular dysfunction, whereas diltiazem is contraindicated in patients with acute myocardial infarction and pulmonary congestion on x-ray.

CCBs are generally not advised for patients with, or at high danger for, heart failure due to decreased left ventricular function. When included in various other therapies, long-acting dihydropyridine substances did not significantly alter prognosis of patients with heart failure [22].A first diuretic was significantly more effective in preventing heart failure compared to any kind of various other drug course, consisting of a CCB [23], [24].CCBs are typically not used alone in patients with renal illness. As an example, amlodipine was inferior to an ACE prevention in avoiding the decline in renal function in nondiabetic African Americans with hypertensive nephrosclerosis [25] and to an angiotensin receptor blocker in patients with hypertension and kind 2 diabetic nephropathy [26].

Common adverse impacts of CCBs include edema, flushing, headache, dizziness, constipation (specifically with high-dose verapamil), nausea, rash, and drowsiness.

CCBs have numerous essential drug communications. Verapamil and diltiazem increase digoxin levels. Verapamil, diltiazem, and nicardipine boost plasma levels and reduce the dosing requirement for cyclosporine. Verapamil and diltiazem are metabolized by CYP3A4, for that reason inducers (eg, rifampin) and preventions (eg, erythromycin, cimetidine) are likely to cause decreased and raised plasma degrees of these 2 CCBs, respectively. Concomitantly administered grapefruit juice elevates the oral bioavailability of felodipine, nifedipine, nicardipine, nisoldipine, and verapamil. As a result of their shared adverse effects on heart rate and myocardial contractility, β-blockers and verapamil are not utilized simultaneously.

- **DUAL CALCIUM CHANNEL BLOCKER THERAPY:**

Pharmacokinetic Aspects:

A pharmacokinetic interaction significantly contributes to the additive reaction of different CCB subclasses. Diltiazem and verapamil are known inhibitors of the cytochrome (CY) P_{450} system [32].Specifically, verapamil and diltiazem inhibit the CYP3A-mediated biotransformation of medications. A sampling of drugs that undergo CYP-3A-mediated biotransformation include simvastatin, [33] lovastatin, [34] cyclosporine, [31] and the aforementioned dihydropyridine CCBs [28], [29], [30].In principle, the communication in between verapamil or diltiazem and a dihydropyridine CCB can be exploited clinically to more efficiently treat the hypertensive patient. Diltiazem appears to inhibit the clearance of nifedipine in a dose-dependent manner [28], [29], [30].This interaction takes place quickly and is almost optimum within 3 days of dosing [30].Less well appreciated is the fact that nifedipine influences the pharmacokinetics of diltiazem. Early observations revealed that pretreatment with nifedipine boosted diltiazem focus, most likely secondarily to both a reduction in its hepatic clearance and a rise in its bioavailability [27].

Pharmacodynamic Aspects:

The pharmacodynamic communication of CCBs leads to greater vasodilation than if only a solitary CCB is given. For instance, the step-up in forearm blood flow that accompanies amlodipine treatment is enhanced by an additional 50% when verapamil is coadministered [34].The system of this augmentation is improperly worked out. It is likely that it belongs, a minimum of in part, to drug-mediated changes in receptor affinity. Drug-induced alterations in receptor binding of CCBs vary from substance to compound. For instance, dihydropyridines inhibit the receptor binding of coadministered dihydropyridines; diltiazem improves receptor binding, [35] whereas verapamil prevents the receptor binding of nitrendipine [36], [37].In spite of the supposedly adverse effect of verapamil on nitrendipine binding, its clinical result is additive, if not synergistic, in minimizing high blood pressure, a finding that, not remarkably, opposes the in vitro binding data [38].

An important factor to consider in CCB pharmacodynamic interaction is the close correlation in between the pharmacodynamic effects of nifedipine and its plasma concentration. A greater plasma degree of nifedipine, and presumably of various other dihydropyridine CCBs, accomplishes a higher hemodynamic impact [37].Although appealing, the clinical significance of the dual CCB pharmacodynamic communication, in the treatment of coronary artery disease and/or systemic hypertension, requires extra research study.

Angina Pectoris:

The largest body of literature assessing the use of dual CCB therapy is in the area of ischemic heart disease. As in the treatment of hypertension, using combination CCB treatment offers clinical benefit to patients who exhibit a subtherapeutic response to single-agent antianginal treatment, particularly when an option, such as a β blocker, is contraindicated (Table 2) [39].

Table 2. Clinical Trials Evaluating Dual Calcium Channel Blocker Therapy in Angina[39].

Reference	Disease and Number of Subjects	Study Design	Monotherapy (Mean Dosage)	Dosage of Dual Therapy	Results of Dual Therapy
Prida et al.8	Coronary artery spasm n=9	R/P-C; D-B mono; O-L dual, cross-over	Diltiazem 90–360 mg/d; nifedipine 30–120 mg/d	Diltiazem 90–360 mg/d (206 mg/d); nifedipine 30–120 mg/d (61 mg/d)	Intolerable adverse effects in 33% (3/9); clinical improvement in 22% (2/9); no improvement in 44% (4/9)
Pucci et al.9	Stable effort angina n=12	D-B/P-C; 4 × 4 400-mg once daily Latin-square	Diltiazem 60 mg × 1 and felodipine 10 mg × 1	Diltiazem 60 mg × 1 with felodipine 10 mg × 1	Prolongation of exercise time to ischemic threshold and to peak exercise; 1 patient with hypotension
Frishman et al.10	Stable effort angina n=13	R/PL, D-B mono; O-L dual, cross-over	Diltiazem 180–360 (352 mg/d) and nifedipine 30–120 mg/d (95 mg/d)	Diltiazem 180–360 (320 mg/d) and nifedipine 30–120 mg/d (52 mg/d)	Improved exercise tolerance and ↓ in angina attacks; ↑ nifedipine concentrations with dual therapy
Toyosaki et al.11	Stable effort angina n=11	R/P-C/D-B, cross-over	Diltiazem 120 mg/d and nifedipine 40 mg/d	Diltiazem 120 mg/d with nifedipine 40 mg/d	↑ exercise time; ↑ nifedipine concentrations with dual therapy

R=randomized; P-C=placebo-controlled; D-B=double-blind; O-L=open-label; PL=placebo

On the basis of positive responses observed in these research studies, it has been recommended that the vasodilator effects of diltiazem are additive to those of a dihydropyridine CCB. The high incidence of adverse results observed in some of these research studies is cause for issue [40].This may take place due to increased nifedipine concentrations, or merely due to the fact that the compounds have comparable adverse event profiles [40].Dual CCB treatment could be particularly

useful when treatment alternatives for symptomatic coronary artery illness are limited by contraindications to other more traditional agents, such as β blockers.

Clinical Implications of Combined CCB Therapy:

Dual CCB administration has been recommended as an effective means of treatment for over a decade; unfortunately, too many questions stay for this to be viewed as a basic type of treatment. For instance, is low-dose dual CCB treatment as effective and safe as optimal CCB monotherapy? There are no straight comparisons in the literature that directly answer this concern. Indirectly, the studies of Andreyev et al. [42] and Nalbantgil et al. [44] show that two CCBs given together in low dosages accomplish better blood pressure control compared to moderate-dosage CCB monotherapy. Also, is dual CCB therapy most effective with low dosage of two agents, or is the mix of a high and low dose of two agents more effective? Kaesemeyer et al. [43] observed that two CCBs provided together in moderate dosages could effectively manage blood pressure in patients with mild hypertension. Alternatively, in patients with moderate to severe hypertension, high-dose combination CCB treatment is needed to get blood pressure control [41].For dual CCB treatment to become a viable therapy alternative, different combinations of CCBs must be officially tested and compared to traditional combinations of antihypertensive agents. Additionally, due to the fact that different combinations of CCBs have not been directly compared with one another, it is unknown whether verapamil or diltiazem is one of the most efficient agent added to a dihydropyridine CCB.

Who are potential candidates for dual CCB therapy? Patients with inadequate blood pressure control while taking several antihypertensive agents could be taken into consideration for dual CCB therapy. In addition, partial responders to optimum tolerated dosages of a single CCB that have relative contraindications to other medication classes appropriate candidates. Unfortunately, until more definitive treatment information appears, dual CCB therapy should be taken into consideration just as a secondary therapy alternative.

4. CONCLUSION

CCBs inhibit Ca2+ channels in the myocardium or vascular smooth muscular tissue cells, resulting in inhibition of myocardium contraction, inhibition of ICS (anti-arrhythmias) and vasodilation. Moreover, CCBs have a pleiotropic effect on CSA including alternative angina, MI and ST. Furthermore, new systems of action of Ca2+ channels, such as the aldosterone inhibition effect and mineralocorticoid receptor blockade impact, have been illuminated in the field of endocrinology. All the calcium blockers have been utilized for managing angina. Nevertheless, the most commonly utilized calcium blockers are the longer-acting types of diltiazem and verapamil, amlodipine, or felodipine.

Nifedipine, especially its short-acting types, need to usually be avoided in patients with angina, because the pronounced blood vessel expansion produced by this medication can increase in adrenaline, resulting in a more fast heart rate, and consequently a rise in cardiac oxygen requirements (which can increase the chances of developing cardiac ischemia). Common negative effects of calcium channel blockers consist of headache, dizziness, flushing, and foot and ankle swelling. Verapamil, particularly, additionally tends to trigger constipation. It is generally best to prevent verapamil and diltiazem in individuals with bradycardia because these drugs will further slow the heart rate.Indirectly, the researches of Andreyev et al. and Nalbantgil et al. show that two CCBs provided together in low dosages accomplish better blood pressure control compared to moderate-dosage CCB monotherapy.

REFERENCES

[1] Fleckenstein A, Nakayama K, Fleckenstein-Grün G, Byon Y. Interactions of H ions, Ca-antagonistic drugs and cardiac glycosides with excitation-contraction coupling of vascular smooth muscle Ionic actions on vascular smooth muscle. Springer 1976, 117–123.

[2] Vater W, Kroneberg G, Hoffmeister F, Saller H, Meng K, Oberdorf A, Puls W, Schlossmann K, Stoepel K. Pharmacology of 4-(2'-nitrophenyl)-2, 6-dimethyl-1, 4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, BAY a 1040). Arzneimittel-Forschung 1972; 22: 1–14.

[3] Fleckenstein A, Tritthart H,Döring H-J,Byron KY. BAY a 1040 — ein hochaktiver Ca++-antagonistischer Inhibitor der elektro-mechanischen Koppelungsprozesse im Warmblüter-Myocard. Arzneimittelforsch 1972; 22: 22–23.

[4] Hashimoto K, Taira N, Sato S, Chiba S, Hashimoto K, Tamura K, Endoh M, Iijima T. Pharmacological action on nitrophenyi-dimethyl-dihydropyridine-deri-vatlveHeart 1971; 3: 1294–1304.

[5] Murakami M, Murakami E, Takekoshi N, Tsuchiya M, Kin T, Onoe T, Takeuchi N, Funatsu T, Hara S, Ishise S. Antihypertensive effect of 4 (-2'-nitrophenyl)-2, 6-dimethyl-1, 4-dihydropyridine-3, 5-dicarbonic acid dimethylester (nifedipine, bay-a 1040), a new coronary dilator. Jpn Heart J 1972; 13: 128–135.

[6] Aoki K, Yoshida T, Kato S, Tazumi K, Sato I, Takikawa K, Hotta K. Hypotensive action and increased plasma renin activity by Ca2+ antagonist (nifedipine) in hypertensive patients. Jpn Heart J 1976; 17: 479–484.

[7] Sato M, Nagao T, Yamaguchi I, Nakajima H, Kiyomoto A. Pharmacological studies on a new l, 5-benzothiazepine derivative (CRD-401). Arzneimittelforschung 1971; 21: 1338.

[8] Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, Omote S, Takaoka K, Okumura K. Long-term prognosis for patients with variant angina and influential factors. Circulation 1988; 78: 1–9.

[9] Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342–353.

[10] Cosnier D, Duchenne-Marullaz P, Rispat G, Streichenberger G. Cardiovascular pharmacology of bepridil (1 [3 isobutoxy 2 (benzylphenyl) amino] propyl pyrrolidine hydrochloride) a new potential anti-anginal compound. Arch Int Pharmacodyn Ther 1977; 225: 133–151.

[11] Yamamoto E, Nakamura T, Kataoka K, Tokutomi Y, Dong Y-F, Fukuda M, Nako H, Yasuda O, Ogawa H, Kim-Mitsuyama S. Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. Biochem Bbiophys Res Commun 2010; 403: 258–263.

[12] Nomura S, Inami N, Kimura Y, Omoto S, Shouzu A, Nishikawa M, Iwasaka T. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 2007; 21: 38–44.

[13] Matsumori A, Nunokawa Y, Sasayama S. Nifedipine inhibits activation of transcription factor NF-κB. Life Sci 2000; 67: 2655–2661.

[14] Rosenkranz AC, Lob H, Breitenbach T, Be JP. Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur J Pharmacol 2006; 529: 55–62.

[15] Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001; 37: 240–245.

[16] Gao X, Iwai M, Inaba S, Tomono Y, Kanno H, Mogi M, Horiuchi M. Attenuation of monocyte chemoattractant protein-1 expression via inhibition of nuclear factor-κB activity in inflammatory vascular injury. Am J Hypertens 2007; 20: 1170–1175.

[17] Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R. Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology 2004; 70: 39–45.

[18] Matsumori A, Nishio R, Nose Y. Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells. Circ J 2010; 74: 567–571.

[19] Sueta D, Nakamura T, Dong Y-F, Kataoka K, Koibuchi N, Yamamoto E, Toyama K, Yasuda O, Ogawa H, Kim-Mitsuyama S. Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. Am J Hypertens 2012; 25: 704–710.

[20] Tulenko T, Sumner A, Chen M, Huang Y, Laury-Kleintop L, Ferdinand F. The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. Am Heart J 2001; 141: S1–S11.

[21] Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res 2014; 37: 253–390.

[22] Cleophas TJ, van Marun R. Meta-analysis of efficacy and safety of second-generation dihydropyridine calcium channel blockers in heart failure. Am J Cardiol. 2001;87:487–490.

[23] Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ.2009;338:b1665.

[24] Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2010;170: 427. epub Nov 8, 2010;

[25] Agodoa LY, Appel L, Bakris GL, et al; For the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719–2728.

[26] Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. Collaborative Study Group. N Engl J Med. 2001;345:841–860.

[27] Tateishi T, Ohashi K, Sudo T, et al. The effect of nifedipine on the pharmacokinetics and dynamic of diltiazem: the preliminary study in normal volunteers. J Clin Pharmacol. 1993;33:738–740.

[28] Ohashi K, Sudo T, Sakamoto K, et al. The influence of pretreatment periods with diltiazem on nifedipine kinetics. J Clin Pharmacol. 1993;33:222–225.

[29] Ohashi K, Tateishi T, Sudo T, et al. Effects of diltiazem on the pharmacokinetics of nifedipine. J Cardiovasc Pharmacol. 1990;15:96–101.

[30] Tateishi T, Ohashi K, Sudo T, et al. Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. J Clin Pharmacol. 1980;29:994–997.

[31] Jacob LP, Malhotra D, Chan L, et al. Absence of a dose-response of cyclosporine levels to clinically used doses of diltiazem and verapamil. Am J Kidney Dis. 1999;33:301–303.

[32] Mousa O, Brater DC, Sunblad KJ, et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000; 67:267–274.

[33] Azie NE, Brater DC, Becker PA, *et al.* The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998*;*64*:*369–377.

[34] Kiowski W, Erne P, Linder L, *et al.* Arterial vasodilator effects of the dihydropyridine calcium antagonist amlodipine alone and in combination with verapamil in systemic hypertension. Am J Cardiol. 1990;66:1469–1472.

[35] Yamamura HI, Schoemaker H, Boles RG, *et al.* Diltiazem enhancement of [3H] nitrendipine to calcium channel associated drug receptor sites in rat brain synaptosomes. Biochem Biophys Res Commun. 1982;108:640–646.

[36] Snyder SH, Reynolds IJ. Calcium-antagonist drugs. Receptor interactions that clarify therapeutic effects. N Engl J Med. 1985*;*313:995–1002.

[37] Ehlert FJ, Roeske WR, Itoga E, *et al.* The binding of [3H] nitrendipine to receptors for calcium channels in the heart, cerebral cortex, and ileum of rats. Life Sci. 1982*;*30*:*2191–2202.

[38] Kleinbloesem CH, Van Brummelen P, Van Den Linde JA, *et al.* Nifedipine; kinetics and dynamics in healthy subjects. Clin Pharmacol Ther. 1984*;*35*:*742–749.

[39] Saseen JJ, Carter BL. Dual calcium-channel blocker therapy in the treatment of hypertension. Ann Pharmacother. 1996;30:802–810.

[40] Prida XE, Gelman JS, Feldman RL, *et al.* Comparison of diltiazem and nifedipine alone and in combination in patients with coronary artery spasm. J Am Coll Cardiol. 1987;9:412–419.

[41] Frishman W, Charlap S, Kimmel B, *et al.* Diltiazem, nifedipine, and their combination in patients with stable angina pectoris: effects on angina, exercise tolerance, and the ambulatory electrocardiographic ST segment. Circulation. 1988;77:1370–1375.

[42] Adreyev N, Buichkov I, Skutelis A, *et al.* Comparison of diltiazem, nitrendipine and their combination for systemic hypertension and stable angina pectoris. J Cardiovasc Pharmacol. 1991; 18 (supp 9):S73–76.

[43] Kaesemeyer WH, Carr AA, Bottini PB, *et al.* Verapamil and nifedipine for the treatment of hypertension. J Clin Pharmacol. 1994;34:48–51.

[44] Nalbantgil I, Onder R, Kiliccioglu B, *et al.* Combination therapy with verapamil and nitrendipine in patients with hypertension. J Hum Hypertens. 1993;7:305–308.